Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the safe and effective use of the
single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon
beta-1a) in participants with multiple sclerosis (MS).